Esther Conde1,2, Alejandra Caminoa1, Carolina Dominguez1, Antonio Calles3, Stefan Walter4,5, Barbara Angulo1,2, Elena Sánchez1, Marta Alonso1, Luis Jimenez6, Luis Madrigal6, Florentino Hernando7, Julian Sanz-Ortega2,8, Beatriz Jimenez9, Pilar Garrido2,10, Luis Paz-Ares2,11, Javier de Castro2,9, Susana Hernandez1, Fernando Lopez-Rios1,2. 1. Pathology-Laboratorio de Dianas Terapeuticas, Hospital Universitario HM Sanchinarro, Universidad CEU San Pablo, Madrid, Spain. 2. Centro de Investigación Biomedica en Red de Cancer (CIBERONC), Madrid, Spain. 3. Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain. 4. Fundación de Investigación Sanitaria de Getafe, Madrid, Spain. 5. University of California San Francisco, San Francisco, CA, USA. 6. Thoracic Surgery, Hospital Universitario HM Sanchinarro, Madrid, Spain. 7. Thoracic Surgery, Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain. 8. Pathology, Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain. 9. Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain. 10. Medical Oncology, IRYCIS, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain. 11. Medical Oncology, Hospital Universitario 12 de Octubre, CNIO and Universidad Complutense, Madrid, Spain.
Abstract
AIMS: To study programmed death ligand 1 (PD-L1) expression, tumour-infiltrating T lymphocytes (TILs) and the molecular context in patients with early-stage squamous cell lung carcinomas (SCCs). METHODS AND RESULTS: The study included samples from 40 patients (discovery cohort) and 29 patients (validation cohort) diagnosed with early-stage SCC. PD-L1 immunohistochemistry (IHC) was performed with three commercially available clones (E1L3N, SP263 and SP142). CD8+ TILs were scored with a digital algorithm. All tumours were analysed with targeted next-generation sequencing (NGS). Additionally, TP53 mutations were investigated with direct sequencing. In both cohorts, we observed a significant association between CD8+ TILs density and high PD-L1 IHC expression in tumour cells (TCs). Furthermore, high SP142 PD-L1 expression in immune cells (ICs) was also associated significantly with CD8+ TILs density. Therefore, CD8+ TILs density discriminated between patients with high versus low PD-L1 IHC expression with excellent sensitivity and specificity. Interestingly, the highest percentages of PD-L1-positive TCs with the three antibodies were found in samples with cyclin-dependent kinase 6 (CDK6) amplification, with high amplification of proto-oncogene C-Myc (CMYC) or with cyclin D1-PI3 kinase subunit alpha (CCND1-PIK3CA) co-amplification. High SP142 PD-L1 IHC expression in ICs showed a non-significant correlation with TP53 mutations. Conversely, most cases with fibroblast growth factor receptor 1 (FGFR1) amplification were negative for all PD-L1 clones. CONCLUSIONS: Our preliminary results support the use of digital CD8+ TILs scoring and targeted NGS alongside PD-L1 expression. The approach presented herein could help define patients with SCCs candidates to immune checkpoints inhibitors.
AIMS: To study programmed death ligand 1 (PD-L1) expression, tumour-infiltrating T lymphocytes (TILs) and the molecular context in patients with early-stage squamous cell lung carcinomas (SCCs). METHODS AND RESULTS: The study included samples from 40 patients (discovery cohort) and 29 patients (validation cohort) diagnosed with early-stage SCC. PD-L1 immunohistochemistry (IHC) was performed with three commercially available clones (E1L3N, SP263 and SP142). CD8+ TILs were scored with a digital algorithm. All tumours were analysed with targeted next-generation sequencing (NGS). Additionally, TP53 mutations were investigated with direct sequencing. In both cohorts, we observed a significant association between CD8+ TILs density and high PD-L1 IHC expression in tumour cells (TCs). Furthermore, high SP142 PD-L1 expression in immune cells (ICs) was also associated significantly with CD8+ TILs density. Therefore, CD8+ TILs density discriminated between patients with high versus low PD-L1 IHC expression with excellent sensitivity and specificity. Interestingly, the highest percentages of PD-L1-positive TCs with the three antibodies were found in samples with cyclin-dependent kinase 6 (CDK6) amplification, with high amplification of proto-oncogene C-Myc (CMYC) or with cyclin D1-PI3 kinase subunit alpha (CCND1-PIK3CA) co-amplification. High SP142 PD-L1 IHC expression in ICs showed a non-significant correlation with TP53 mutations. Conversely, most cases with fibroblast growth factor receptor 1 (FGFR1) amplification were negative for all PD-L1 clones. CONCLUSIONS: Our preliminary results support the use of digital CD8+ TILs scoring and targeted NGS alongside PD-L1 expression. The approach presented herein could help define patients with SCCs candidates to immune checkpoints inhibitors.
Authors: P Garrido; E Conde; J de Castro; J J Gómez-Román; E Felip; L Pijuan; D Isla; J Sanz; L Paz-Ares; F López-Ríos Journal: Clin Transl Oncol Date: 2019-10-09 Impact factor: 3.405